methyldopa pivaloyloxyethyl ester: prodrug of methyldopa; RN given refers to parent cpd; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 88126 |
| SCHEMBL ID | 10416847 |
| MeSH ID | M0114407 |
| Synonym |
|---|
| methyldopa pivaloyloxyethyl ester |
| 81660-38-0 |
| 1-(2,2-dimethylpropionyloxy)ethyl 3-hydroxy-alpha-methyl-l-tyrosinate |
| l-tyrosine, 3-hydroxy-alpha-methyl-, 1-(2,2-dimethyl-1-oxopropoxy)ethyl ester |
| wbi8so7k59 , |
| einecs 279-793-2 |
| unii-wbi8so7k59 |
| alpha-pivaloyloxyethyl (s)-3-(3,4-dihydroxyphenyl)-2-methylalaninate |
| IFDYIWPAJKYNTO-LKDXBUKQSA-N |
| SCHEMBL10416847 |
| 3-hydroxy-alpha-methyl-l-tyrosine 1-(2,2-dimethyl-1-oxopropoxy)ethyl ester |
| l-tyrosine, 3-hydroxy-.alpha.-methyl-, 1-(2,2-dimethyl-1-oxopropoxy)ethyl ester |
| DTXSID301002119 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " Thus, the oral dose of POE was well absorbed and rapidly hydrolyzed to methyldopa." | ( Metabolism of methyldopa in man after oral administration of the pivaloyloxyethyl ester. Dobrinska, MR; Dollery, CT; Duncan, CA; Gomez, HJ; Leidy, HL; Ramjit, HG; Vickers, S; Vincek, WC, ) | 0.13 |
| "The pivaloyloxyethyl ester of methyldopa is an antihypertensive prodrug possessing improved bioavailability properties over methyldopa." | ( Sensitive high-performance liquid chromatographic assay using electrochemical detection for a novel prodrug ester of methyldopa, pivaloyloxyethyl 3-(3,4-dihydroxyphenyl)-2-methylalaninate, in plasma and urine. Dobrinska, MR; Leidy, HL; Musson, DG; Vickers, S; Vincek, WC, 1984) | 0.27 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 5 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.37) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (14.29%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (85.71%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||